Animal Health Research Center, Department of Infectious Diseases, University of Georgia, Athens, Georgia, USA.
Respiratory Virology Group, Centre for Research in Therapeutic Solutions, Faculty of Science and Technology, University of Canberra, Canberra, Australia.
J Virol. 2019 Feb 5;93(4). doi: 10.1128/JVI.01684-18. Print 2019 Feb 15.
Respiratory syncytial virus (RSV) is a leading cause of hospitalization of infants and young children, causing considerable respiratory disease and repeat infections that may lead to chronic respiratory conditions such as asthma, wheezing, and bronchitis. RSV causes ∼34 million new episodes of lower respiratory tract illness (LRTI) in children younger than 5 years of age, with >3 million hospitalizations due to severe RSV-associated LRTI. The standard of care is limited to symptomatic relief as there are no approved vaccines and few effective antiviral drugs; thus, a safe and efficacious RSV therapeutic is needed. Therapeutic targeting of host proteins hijacked by RSV to facilitate replication is a promising antiviral strategy as targeting the host reduces the likelihood of developing drug resistance. The nuclear export of the RSV M protein, mediated by the nuclear export protein exportin 1 (XPO1), is crucial for RSV assembly and budding. Inhibition of RSV M protein export by leptomycin B correlated with reduced RSV replication In this study, we evaluated the anti-RSV efficacy of Verdinexor (KPT-335), a small molecule designed to reversibly inhibit XPO1-mediated nuclear export. KPT-335 inhibited XPO1-mediated transport and reduced RSV replication KPT-335 was effective against RSV A and B strains and reduced viral replication following prophylactic or therapeutic administration. Inhibition of RSV replication by KPT-335 was due to a combined effect of reduced XPO1 expression, disruption of the nuclear export of RSV M protein, and inactivation of the NF-κB signaling pathway. RSV is an important cause of LRTI in infants and young children for which there are no suitable antiviral drugs offered. We evaluated the efficacy of KPT-335 as an anti-RSV drug and show that KPT-335 inhibits XPO1-mediated nuclear export, leading to nuclear accumulation of RSV M protein and reduction in RSV levels. KPT-335 treatment also resulted in inhibition of proinflammatory pathways, which has important implications for its effectiveness .
呼吸道合胞病毒(RSV)是导致婴儿和幼儿住院的主要原因,会引起严重的呼吸道疾病,并导致反复感染,从而可能导致哮喘、喘息和支气管炎等慢性呼吸道疾病。RSV 导致 5 岁以下儿童发生约 3400 万例新的下呼吸道疾病(LRTI),其中因严重 RSV 相关 LRTI 导致 300 多万人住院。由于没有批准的疫苗和很少有效的抗病毒药物,因此目前的治疗标准仅限于对症缓解,因此需要一种安全有效的 RSV 治疗药物。针对 RSV 劫持宿主蛋白以促进复制的治疗方法是一种很有前途的抗病毒策略,因为针对宿主可以降低产生耐药性的可能性。RSV M 蛋白的核输出由核输出蛋白 exportin 1(XPO1)介导,这对于 RSV 的组装和出芽至关重要。莱普霉素 B 抑制 RSV M 蛋白的输出与 RSV 复制减少相关。在这项研究中,我们评估了 Verdinexor(KPT-335)的抗 RSV 疗效,Verdinexor 是一种设计用于可逆抑制 XPO1 介导的核输出的小分子。KPT-335 抑制 XPO1 介导的运输并减少 RSV 复制。KPT-335 对 RSV A 和 B 株有效,并在预防性或治疗性给药后减少病毒复制。KPT-335 通过减少 XPO1 表达、破坏 RSV M 蛋白的核输出以及失活 NF-κB 信号通路来抑制 RSV 复制。RSV 是导致婴儿和幼儿 LRTI 的重要原因,但目前尚无有效的抗病毒药物。我们评估了 KPT-335 作为抗 RSV 药物的疗效,并表明 KPT-335 抑制 XPO1 介导的核输出,导致 RSV M 蛋白在核内积累并减少 RSV 水平。KPT-335 治疗还导致促炎途径的抑制,这对其有效性具有重要意义。